Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Identifieur interne : 001F60 ( PubMed/Checkpoint ); précédent : 001F59; suivant : 001F61Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Auteurs : Vlad Ratziu [France] ; Stephen A. Harrison [États-Unis] ; Sven Francque [Belgique] ; Pierre Bedossa [France] ; Philippe Lehert [Belgique] ; Lawrence Serfaty [France] ; Manuel Romero-Gomez ; Jérôme Boursier [France] ; Manal Abdelmalek [États-Unis] ; Steve Caldwell [États-Unis] ; Joost Drenth [Pays-Bas] ; Quentin M. Anstee [Royaume-Uni] ; Dean Hum [France] ; Remy Hanf [France] ; Alice Roudot [France] ; Sophie Megnien [France] ; Bart Staels [France] ; Arun Sanyal [États-Unis]Source :
- Gastroenterology [ 1528-0012 ] ; 2016.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Agents gastro-intestinaux (administration et posologie), Agents gastro-intestinaux (effets indésirables), Analyse de l'intention de traiter, Biopsie, Chalcones (administration et posologie), Chalcones (effets indésirables), Cirrhose du foie (étiologie), Europe, Facteurs temps, Femelle, Foie (), Foie (anatomopathologie), Foie (métabolisme), Humains, Indice de gravité médicale, Induction de rémission, Marqueurs biologiques (sang), Modèles logistiques, Mâle, Méthode en double aveugle, Odds ratio, Propionates (administration et posologie), Propionates (effets indésirables), Récepteur PPAR alpha (agonistes), Récepteur PPAR alpha (métabolisme), Récepteur PPAR gamma (agonistes), Récepteur PPAR gamma (métabolisme), Résultat thérapeutique, Stéatose hépatique non alcoolique (), Stéatose hépatique non alcoolique (anatomopathologie), Stéatose hépatique non alcoolique (métabolisme), Stéatose hépatique non alcoolique (traitement médicamenteux), Transduction du signal (), États-Unis d'Amérique.
- MESH :
- administration et posologie : Agents gastro-intestinaux, Chalcones, Propionates.
- agonistes : Récepteur PPAR alpha, Récepteur PPAR gamma.
- anatomopathologie : Foie, Stéatose hépatique non alcoolique.
- effets indésirables : Agents gastro-intestinaux, Chalcones, Propionates.
- métabolisme : Foie, Récepteur PPAR alpha, Récepteur PPAR gamma, Stéatose hépatique non alcoolique.
- sang : Marqueurs biologiques.
- traitement médicamenteux : Stéatose hépatique non alcoolique.
- étiologie : Cirrhose du foie.
- Adulte, Adulte d'âge moyen, Analyse de l'intention de traiter, Biopsie, Europe, Facteurs temps, Femelle, Foie, Humains, Indice de gravité médicale, Induction de rémission, Modèles logistiques, Mâle, Méthode en double aveugle, Odds ratio, Résultat thérapeutique, Stéatose hépatique non alcoolique, Transduction du signal, États-Unis d'Amérique.
English descriptors
- KwdEn :
- Adult, Biomarkers (blood), Biopsy, Chalcones (administration & dosage), Chalcones (adverse effects), Double-Blind Method, Europe, Female, Gastrointestinal Agents (administration & dosage), Gastrointestinal Agents (adverse effects), Humans, Intention to Treat Analysis, Liver (drug effects), Liver (metabolism), Liver (pathology), Liver Cirrhosis (etiology), Logistic Models, Male, Middle Aged, Non-alcoholic Fatty Liver Disease (complications), Non-alcoholic Fatty Liver Disease (drug therapy), Non-alcoholic Fatty Liver Disease (metabolism), Non-alcoholic Fatty Liver Disease (pathology), Odds Ratio, PPAR alpha (agonists), PPAR alpha (metabolism), PPAR gamma (agonists), PPAR gamma (metabolism), Propionates (administration & dosage), Propionates (adverse effects), Remission Induction, Severity of Illness Index, Signal Transduction (drug effects), Time Factors, Treatment Outcome, United States.
- MESH :
- chemical , administration & dosage : Chalcones, Gastrointestinal Agents, Propionates.
- chemical , adverse effects : Chalcones, Gastrointestinal Agents, Propionates.
- chemical , agonists : PPAR alpha, PPAR gamma.
- chemical , blood : Biomarkers.
- complications : Non-alcoholic Fatty Liver Disease.
- drug effects : Liver, Signal Transduction.
- drug therapy : Non-alcoholic Fatty Liver Disease.
- etiology : Liver Cirrhosis.
- metabolism : Liver, Non-alcoholic Fatty Liver Disease, PPAR alpha, PPAR gamma.
- pathology : Liver, Non-alcoholic Fatty Liver Disease.
- Adult, Biopsy, Double-Blind Method, Europe, Female, Humans, Intention to Treat Analysis, Logistic Models, Male, Middle Aged, Odds Ratio, Remission Induction, Severity of Illness Index, Time Factors, Treatment Outcome, United States.
Abstract
Elafibranor is an agonist of the peroxisome proliferator-activated receptor-α and peroxisome proliferator-activated receptor-δ. Elafibranor improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammation. We assessed the safety and efficacy of elafibranor in an international, randomized, double-blind placebo-controlled trial of patients with nonalcoholic steatohepatitis (NASH).
DOI: 10.1053/j.gastro.2016.01.038
PubMed: 26874076
Affiliations:
- Belgique, France, Pays-Bas, Royaume-Uni, États-Unis
- Caroline du Nord, Gueldre, Hauts-de-France, Nord-Pas-de-Calais, Pays de la Loire, Texas, Victoria (État), Virginie, Île-de-France
- Angers, Lille, Melbourne, Nimègue, Paris
- Université Pierre-et-Marie-Curie, Université de Melbourne
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:26874076Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.</title><author><name sortKey="Ratziu, Vlad" sort="Ratziu, Vlad" uniqKey="Ratziu V" first="Vlad" last="Ratziu">Vlad Ratziu</name><affiliation wicri:level="4"><nlm:affiliation>Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière, Paris, France; Institute of Cardiometabolism and Nutrition, INSERM, UMRS 938, Paris, France. Electronic address: vlad.ratziu@upmc.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière, Paris, France; Institute of Cardiometabolism and Nutrition, INSERM, UMRS 938, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement><settlement type="city">Paris</settlement></placeName><orgName type="university">Université Pierre-et-Marie-Curie</orgName></affiliation></author><author><name sortKey="Harrison, Stephen A" sort="Harrison, Stephen A" uniqKey="Harrison S" first="Stephen A" last="Harrison">Stephen A. Harrison</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Gastroenterology and Hepatology Service, Brooke Army Medical Center, Fort Sam Houston, Texas.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Department of Medicine, Gastroenterology and Hepatology Service, Brooke Army Medical Center, Fort Sam Houston</wicri:cityArea></affiliation></author><author><name sortKey="Francque, Sven" sort="Francque, Sven" uniqKey="Francque S" first="Sven" last="Francque">Sven Francque</name><affiliation wicri:level="1"><nlm:affiliation>Department of Gastroenterology and Hepatology, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Gastroenterology and Hepatology, Antwerp University Hospital, University of Antwerp, Antwerp</wicri:regionArea><wicri:noRegion>Antwerp</wicri:noRegion></affiliation></author><author><name sortKey="Bedossa, Pierre" sort="Bedossa, Pierre" uniqKey="Bedossa P" first="Pierre" last="Bedossa">Pierre Bedossa</name><affiliation wicri:level="3"><nlm:affiliation>Department of Pathology, Hôpital Beaujon, University Paris-Denis Diderot, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Pathology, Hôpital Beaujon, University Paris-Denis Diderot, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Lehert, Philippe" sort="Lehert, Philippe" uniqKey="Lehert P" first="Philippe" last="Lehert">Philippe Lehert</name><affiliation wicri:level="4"><nlm:affiliation>Department of Psychiatry, the University of Melbourne, Melbourne, Australia; Faculty of Economics, University of Louvain UCL, Belgique, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Psychiatry, the University of Melbourne, Melbourne, Australia; Faculty of Economics, University of Louvain UCL, Belgique</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Serfaty, Lawrence" sort="Serfaty, Lawrence" uniqKey="Serfaty L" first="Lawrence" last="Serfaty">Lawrence Serfaty</name><affiliation wicri:level="4"><nlm:affiliation>Université Pierre et Marie Curie, Hôpital Saint-Antoine, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université Pierre et Marie Curie, Hôpital Saint-Antoine, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement><settlement type="city">Paris</settlement></placeName><orgName type="university">Université Pierre-et-Marie-Curie</orgName></affiliation></author><author><name sortKey="Romero Gomez, Manuel" sort="Romero Gomez, Manuel" uniqKey="Romero Gomez M" first="Manuel" last="Romero-Gomez">Manuel Romero-Gomez</name><affiliation><nlm:affiliation>Unit for the Clinical Management of Digestive Diseases and CIBERehd, Hospital Universitario de Valme, Sevilla.</nlm:affiliation><wicri:noCountry code="subField">Sevilla</wicri:noCountry></affiliation></author><author><name sortKey="Boursier, Jerome" sort="Boursier, Jerome" uniqKey="Boursier J" first="Jérôme" last="Boursier">Jérôme Boursier</name><affiliation wicri:level="3"><nlm:affiliation>Hepatology Department, University Hospital and LUNAM University, Angers, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hepatology Department, University Hospital and LUNAM University, Angers</wicri:regionArea><placeName><region type="region">Pays de la Loire</region><region type="old region">Pays de la Loire</region><settlement type="city">Angers</settlement></placeName></affiliation></author><author><name sortKey="Abdelmalek, Manal" sort="Abdelmalek, Manal" uniqKey="Abdelmalek M" first="Manal" last="Abdelmalek">Manal Abdelmalek</name><affiliation wicri:level="2"><nlm:affiliation>Duke University, Durham, North Carolina.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Caroline du Nord</region></placeName><wicri:cityArea>Duke University, Durham</wicri:cityArea></affiliation></author><author><name sortKey="Caldwell, Steve" sort="Caldwell, Steve" uniqKey="Caldwell S" first="Steve" last="Caldwell">Steve Caldwell</name><affiliation wicri:level="2"><nlm:affiliation>Gastroenterology and Hepatology Division, University of Virginia, Charlottesville, Virginia.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Virginie</region></placeName><wicri:cityArea>Gastroenterology and Hepatology Division, University of Virginia, Charlottesville</wicri:cityArea></affiliation></author><author><name sortKey="Drenth, Joost" sort="Drenth, Joost" uniqKey="Drenth J" first="Joost" last="Drenth">Joost Drenth</name><affiliation wicri:level="3"><nlm:affiliation>Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen</wicri:regionArea><placeName><settlement type="city">Nimègue</settlement><region type="province" nuts="2">Gueldre</region></placeName></affiliation></author><author><name sortKey="Anstee, Quentin M" sort="Anstee, Quentin M" uniqKey="Anstee Q" first="Quentin M" last="Anstee">Quentin M. Anstee</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Cellular Medicine, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Cellular Medicine, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne</wicri:regionArea><wicri:noRegion>Newcastle upon Tyne</wicri:noRegion></affiliation></author><author><name sortKey="Hum, Dean" sort="Hum, Dean" uniqKey="Hum D" first="Dean" last="Hum">Dean Hum</name><affiliation wicri:level="1"><nlm:affiliation>Genfit SA, Loos, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Genfit SA, Loos</wicri:regionArea><wicri:noRegion>Loos</wicri:noRegion><wicri:noRegion>Loos</wicri:noRegion></affiliation></author><author><name sortKey="Hanf, Remy" sort="Hanf, Remy" uniqKey="Hanf R" first="Remy" last="Hanf">Remy Hanf</name><affiliation wicri:level="1"><nlm:affiliation>Genfit SA, Loos, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Genfit SA, Loos</wicri:regionArea><wicri:noRegion>Loos</wicri:noRegion><wicri:noRegion>Loos</wicri:noRegion></affiliation></author><author><name sortKey="Roudot, Alice" sort="Roudot, Alice" uniqKey="Roudot A" first="Alice" last="Roudot">Alice Roudot</name><affiliation wicri:level="1"><nlm:affiliation>Genfit SA, Loos, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Genfit SA, Loos</wicri:regionArea><wicri:noRegion>Loos</wicri:noRegion><wicri:noRegion>Loos</wicri:noRegion></affiliation></author><author><name sortKey="Megnien, Sophie" sort="Megnien, Sophie" uniqKey="Megnien S" first="Sophie" last="Megnien">Sophie Megnien</name><affiliation wicri:level="1"><nlm:affiliation>Genfit SA, Loos, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Genfit SA, Loos</wicri:regionArea><wicri:noRegion>Loos</wicri:noRegion><wicri:noRegion>Loos</wicri:noRegion></affiliation></author><author><name sortKey="Staels, Bart" sort="Staels, Bart" uniqKey="Staels B" first="Bart" last="Staels">Bart Staels</name><affiliation wicri:level="3"><nlm:affiliation>University of Lille, INSERM UMR1011, Institut Pasteur de Lille, European Genomic Institute for Diabetes, Lille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>University of Lille, INSERM UMR1011, Institut Pasteur de Lille, European Genomic Institute for Diabetes, Lille</wicri:regionArea><placeName><region type="region">Hauts-de-France</region><region type="old region">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Sanyal, Arun" sort="Sanyal, Arun" uniqKey="Sanyal A" first="Arun" last="Sanyal">Arun Sanyal</name><affiliation wicri:level="2"><nlm:affiliation>Virginia Commonwealth University, Richmond, Virginia.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Virginie</region></placeName><wicri:cityArea>Virginia Commonwealth University, Richmond</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26874076</idno><idno type="pmid">26874076</idno><idno type="doi">10.1053/j.gastro.2016.01.038</idno><idno type="wicri:Area/PubMed/Corpus">001F51</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001F51</idno><idno type="wicri:Area/PubMed/Curation">001F27</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001F27</idno><idno type="wicri:Area/PubMed/Checkpoint">001F27</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001F27</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.</title><author><name sortKey="Ratziu, Vlad" sort="Ratziu, Vlad" uniqKey="Ratziu V" first="Vlad" last="Ratziu">Vlad Ratziu</name><affiliation wicri:level="4"><nlm:affiliation>Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière, Paris, France; Institute of Cardiometabolism and Nutrition, INSERM, UMRS 938, Paris, France. Electronic address: vlad.ratziu@upmc.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière, Paris, France; Institute of Cardiometabolism and Nutrition, INSERM, UMRS 938, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement><settlement type="city">Paris</settlement></placeName><orgName type="university">Université Pierre-et-Marie-Curie</orgName></affiliation></author><author><name sortKey="Harrison, Stephen A" sort="Harrison, Stephen A" uniqKey="Harrison S" first="Stephen A" last="Harrison">Stephen A. Harrison</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Gastroenterology and Hepatology Service, Brooke Army Medical Center, Fort Sam Houston, Texas.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Department of Medicine, Gastroenterology and Hepatology Service, Brooke Army Medical Center, Fort Sam Houston</wicri:cityArea></affiliation></author><author><name sortKey="Francque, Sven" sort="Francque, Sven" uniqKey="Francque S" first="Sven" last="Francque">Sven Francque</name><affiliation wicri:level="1"><nlm:affiliation>Department of Gastroenterology and Hepatology, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Gastroenterology and Hepatology, Antwerp University Hospital, University of Antwerp, Antwerp</wicri:regionArea><wicri:noRegion>Antwerp</wicri:noRegion></affiliation></author><author><name sortKey="Bedossa, Pierre" sort="Bedossa, Pierre" uniqKey="Bedossa P" first="Pierre" last="Bedossa">Pierre Bedossa</name><affiliation wicri:level="3"><nlm:affiliation>Department of Pathology, Hôpital Beaujon, University Paris-Denis Diderot, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Pathology, Hôpital Beaujon, University Paris-Denis Diderot, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Lehert, Philippe" sort="Lehert, Philippe" uniqKey="Lehert P" first="Philippe" last="Lehert">Philippe Lehert</name><affiliation wicri:level="4"><nlm:affiliation>Department of Psychiatry, the University of Melbourne, Melbourne, Australia; Faculty of Economics, University of Louvain UCL, Belgique, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Psychiatry, the University of Melbourne, Melbourne, Australia; Faculty of Economics, University of Louvain UCL, Belgique</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Serfaty, Lawrence" sort="Serfaty, Lawrence" uniqKey="Serfaty L" first="Lawrence" last="Serfaty">Lawrence Serfaty</name><affiliation wicri:level="4"><nlm:affiliation>Université Pierre et Marie Curie, Hôpital Saint-Antoine, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université Pierre et Marie Curie, Hôpital Saint-Antoine, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement><settlement type="city">Paris</settlement></placeName><orgName type="university">Université Pierre-et-Marie-Curie</orgName></affiliation></author><author><name sortKey="Romero Gomez, Manuel" sort="Romero Gomez, Manuel" uniqKey="Romero Gomez M" first="Manuel" last="Romero-Gomez">Manuel Romero-Gomez</name><affiliation><nlm:affiliation>Unit for the Clinical Management of Digestive Diseases and CIBERehd, Hospital Universitario de Valme, Sevilla.</nlm:affiliation><wicri:noCountry code="subField">Sevilla</wicri:noCountry></affiliation></author><author><name sortKey="Boursier, Jerome" sort="Boursier, Jerome" uniqKey="Boursier J" first="Jérôme" last="Boursier">Jérôme Boursier</name><affiliation wicri:level="3"><nlm:affiliation>Hepatology Department, University Hospital and LUNAM University, Angers, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hepatology Department, University Hospital and LUNAM University, Angers</wicri:regionArea><placeName><region type="region">Pays de la Loire</region><region type="old region">Pays de la Loire</region><settlement type="city">Angers</settlement></placeName></affiliation></author><author><name sortKey="Abdelmalek, Manal" sort="Abdelmalek, Manal" uniqKey="Abdelmalek M" first="Manal" last="Abdelmalek">Manal Abdelmalek</name><affiliation wicri:level="2"><nlm:affiliation>Duke University, Durham, North Carolina.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Caroline du Nord</region></placeName><wicri:cityArea>Duke University, Durham</wicri:cityArea></affiliation></author><author><name sortKey="Caldwell, Steve" sort="Caldwell, Steve" uniqKey="Caldwell S" first="Steve" last="Caldwell">Steve Caldwell</name><affiliation wicri:level="2"><nlm:affiliation>Gastroenterology and Hepatology Division, University of Virginia, Charlottesville, Virginia.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Virginie</region></placeName><wicri:cityArea>Gastroenterology and Hepatology Division, University of Virginia, Charlottesville</wicri:cityArea></affiliation></author><author><name sortKey="Drenth, Joost" sort="Drenth, Joost" uniqKey="Drenth J" first="Joost" last="Drenth">Joost Drenth</name><affiliation wicri:level="3"><nlm:affiliation>Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen</wicri:regionArea><placeName><settlement type="city">Nimègue</settlement><region type="province" nuts="2">Gueldre</region></placeName></affiliation></author><author><name sortKey="Anstee, Quentin M" sort="Anstee, Quentin M" uniqKey="Anstee Q" first="Quentin M" last="Anstee">Quentin M. Anstee</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Cellular Medicine, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Cellular Medicine, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne</wicri:regionArea><wicri:noRegion>Newcastle upon Tyne</wicri:noRegion></affiliation></author><author><name sortKey="Hum, Dean" sort="Hum, Dean" uniqKey="Hum D" first="Dean" last="Hum">Dean Hum</name><affiliation wicri:level="1"><nlm:affiliation>Genfit SA, Loos, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Genfit SA, Loos</wicri:regionArea><wicri:noRegion>Loos</wicri:noRegion><wicri:noRegion>Loos</wicri:noRegion></affiliation></author><author><name sortKey="Hanf, Remy" sort="Hanf, Remy" uniqKey="Hanf R" first="Remy" last="Hanf">Remy Hanf</name><affiliation wicri:level="1"><nlm:affiliation>Genfit SA, Loos, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Genfit SA, Loos</wicri:regionArea><wicri:noRegion>Loos</wicri:noRegion><wicri:noRegion>Loos</wicri:noRegion></affiliation></author><author><name sortKey="Roudot, Alice" sort="Roudot, Alice" uniqKey="Roudot A" first="Alice" last="Roudot">Alice Roudot</name><affiliation wicri:level="1"><nlm:affiliation>Genfit SA, Loos, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Genfit SA, Loos</wicri:regionArea><wicri:noRegion>Loos</wicri:noRegion><wicri:noRegion>Loos</wicri:noRegion></affiliation></author><author><name sortKey="Megnien, Sophie" sort="Megnien, Sophie" uniqKey="Megnien S" first="Sophie" last="Megnien">Sophie Megnien</name><affiliation wicri:level="1"><nlm:affiliation>Genfit SA, Loos, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Genfit SA, Loos</wicri:regionArea><wicri:noRegion>Loos</wicri:noRegion><wicri:noRegion>Loos</wicri:noRegion></affiliation></author><author><name sortKey="Staels, Bart" sort="Staels, Bart" uniqKey="Staels B" first="Bart" last="Staels">Bart Staels</name><affiliation wicri:level="3"><nlm:affiliation>University of Lille, INSERM UMR1011, Institut Pasteur de Lille, European Genomic Institute for Diabetes, Lille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>University of Lille, INSERM UMR1011, Institut Pasteur de Lille, European Genomic Institute for Diabetes, Lille</wicri:regionArea><placeName><region type="region">Hauts-de-France</region><region type="old region">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Sanyal, Arun" sort="Sanyal, Arun" uniqKey="Sanyal A" first="Arun" last="Sanyal">Arun Sanyal</name><affiliation wicri:level="2"><nlm:affiliation>Virginia Commonwealth University, Richmond, Virginia.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Virginie</region></placeName><wicri:cityArea>Virginia Commonwealth University, Richmond</wicri:cityArea></affiliation></author></analytic><series><title level="j">Gastroenterology</title><idno type="eISSN">1528-0012</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Biomarkers (blood)</term><term>Biopsy</term><term>Chalcones (administration & dosage)</term><term>Chalcones (adverse effects)</term><term>Double-Blind Method</term><term>Europe</term><term>Female</term><term>Gastrointestinal Agents (administration & dosage)</term><term>Gastrointestinal Agents (adverse effects)</term><term>Humans</term><term>Intention to Treat Analysis</term><term>Liver (drug effects)</term><term>Liver (metabolism)</term><term>Liver (pathology)</term><term>Liver Cirrhosis (etiology)</term><term>Logistic Models</term><term>Male</term><term>Middle Aged</term><term>Non-alcoholic Fatty Liver Disease (complications)</term><term>Non-alcoholic Fatty Liver Disease (drug therapy)</term><term>Non-alcoholic Fatty Liver Disease (metabolism)</term><term>Non-alcoholic Fatty Liver Disease (pathology)</term><term>Odds Ratio</term><term>PPAR alpha (agonists)</term><term>PPAR alpha (metabolism)</term><term>PPAR gamma (agonists)</term><term>PPAR gamma (metabolism)</term><term>Propionates (administration & dosage)</term><term>Propionates (adverse effects)</term><term>Remission Induction</term><term>Severity of Illness Index</term><term>Signal Transduction (drug effects)</term><term>Time Factors</term><term>Treatment Outcome</term><term>United States</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Agents gastro-intestinaux (administration et posologie)</term><term>Agents gastro-intestinaux (effets indésirables)</term><term>Analyse de l'intention de traiter</term><term>Biopsie</term><term>Chalcones (administration et posologie)</term><term>Chalcones (effets indésirables)</term><term>Cirrhose du foie (étiologie)</term><term>Europe</term><term>Facteurs temps</term><term>Femelle</term><term>Foie ()</term><term>Foie (anatomopathologie)</term><term>Foie (métabolisme)</term><term>Humains</term><term>Indice de gravité médicale</term><term>Induction de rémission</term><term>Marqueurs biologiques (sang)</term><term>Modèles logistiques</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Odds ratio</term><term>Propionates (administration et posologie)</term><term>Propionates (effets indésirables)</term><term>Récepteur PPAR alpha (agonistes)</term><term>Récepteur PPAR alpha (métabolisme)</term><term>Récepteur PPAR gamma (agonistes)</term><term>Récepteur PPAR gamma (métabolisme)</term><term>Résultat thérapeutique</term><term>Stéatose hépatique non alcoolique ()</term><term>Stéatose hépatique non alcoolique (anatomopathologie)</term><term>Stéatose hépatique non alcoolique (métabolisme)</term><term>Stéatose hépatique non alcoolique (traitement médicamenteux)</term><term>Transduction du signal ()</term><term>États-Unis d'Amérique</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Chalcones</term><term>Gastrointestinal Agents</term><term>Propionates</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Chalcones</term><term>Gastrointestinal Agents</term><term>Propionates</term></keywords><keywords scheme="MESH" type="chemical" qualifier="agonists" xml:lang="en"><term>PPAR alpha</term><term>PPAR gamma</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Biomarkers</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Agents gastro-intestinaux</term><term>Chalcones</term><term>Propionates</term></keywords><keywords scheme="MESH" qualifier="agonistes" xml:lang="fr"><term>Récepteur PPAR alpha</term><term>Récepteur PPAR gamma</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Foie</term><term>Stéatose hépatique non alcoolique</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Non-alcoholic Fatty Liver Disease</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Liver</term><term>Signal Transduction</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Non-alcoholic Fatty Liver Disease</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Agents gastro-intestinaux</term><term>Chalcones</term><term>Propionates</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Liver Cirrhosis</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Liver</term><term>Non-alcoholic Fatty Liver Disease</term><term>PPAR alpha</term><term>PPAR gamma</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Foie</term><term>Récepteur PPAR alpha</term><term>Récepteur PPAR gamma</term><term>Stéatose hépatique non alcoolique</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Liver</term><term>Non-alcoholic Fatty Liver Disease</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Marqueurs biologiques</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Stéatose hépatique non alcoolique</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Cirrhose du foie</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Biopsy</term><term>Double-Blind Method</term><term>Europe</term><term>Female</term><term>Humans</term><term>Intention to Treat Analysis</term><term>Logistic Models</term><term>Male</term><term>Middle Aged</term><term>Odds Ratio</term><term>Remission Induction</term><term>Severity of Illness Index</term><term>Time Factors</term><term>Treatment Outcome</term><term>United States</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Analyse de l'intention de traiter</term><term>Biopsie</term><term>Europe</term><term>Facteurs temps</term><term>Femelle</term><term>Foie</term><term>Humains</term><term>Indice de gravité médicale</term><term>Induction de rémission</term><term>Modèles logistiques</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Odds ratio</term><term>Résultat thérapeutique</term><term>Stéatose hépatique non alcoolique</term><term>Transduction du signal</term><term>États-Unis d'Amérique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Elafibranor is an agonist of the peroxisome proliferator-activated receptor-α and peroxisome proliferator-activated receptor-δ. Elafibranor improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammation. We assessed the safety and efficacy of elafibranor in an international, randomized, double-blind placebo-controlled trial of patients with nonalcoholic steatohepatitis (NASH).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26874076</PMID><DateCreated><Year>2016</Year><Month>04</Month><Day>24</Day></DateCreated><DateCompleted><Year>2017</Year><Month>03</Month><Day>28</Day></DateCompleted><DateRevised><Year>2017</Year><Month>08</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1528-0012</ISSN><JournalIssue CitedMedium="Internet"><Volume>150</Volume><Issue>5</Issue><PubDate><Year>2016</Year><Month>05</Month></PubDate></JournalIssue><Title>Gastroenterology</Title><ISOAbbreviation>Gastroenterology</ISOAbbreviation></Journal><ArticleTitle>Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.</ArticleTitle><Pagination><MedlinePgn>1147-1159.e5</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0016-5085(16)00140-2</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1053/j.gastro.2016.01.038</ELocationID><Abstract><AbstractText Label="BACKGROUND & AIMS">Elafibranor is an agonist of the peroxisome proliferator-activated receptor-α and peroxisome proliferator-activated receptor-δ. Elafibranor improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammation. We assessed the safety and efficacy of elafibranor in an international, randomized, double-blind placebo-controlled trial of patients with nonalcoholic steatohepatitis (NASH).</AbstractText><AbstractText Label="METHODS">Patients with NASH without cirrhosis were randomly assigned to groups given elafibranor 80 mg (n = 93), elafibranor 120 mg (n = 91), or placebo (n = 92) each day for 52 weeks at sites in Europe and the United States. Clinical and laboratory evaluations were performed every 2 months during this 1-year period. Liver biopsies were then collected and patients were assessed 3 months later. The primary outcome was resolution of NASH without fibrosis worsening, using protocol-defined and modified definitions. Data from the groups given the different doses of elafibranor were compared with those from the placebo group using step-down logistic regression, adjusting for baseline nonalcoholic fatty liver disease activity score.</AbstractText><AbstractText Label="RESULTS">In intention-to-treat analysis, there was no significant difference between the elafibranor and placebo groups in the protocol-defined primary outcome. However, NASH resolved without fibrosis worsening in a higher proportion of patients in the 120-mg elafibranor group vs the placebo group (19% vs 12%; odds ratio = 2.31; 95% confidence interval: 1.02-5.24; P = .045), based on a post-hoc analysis for the modified definition. In post-hoc analyses of patients with nonalcoholic fatty liver disease activity score ≥4 (n = 234), elafibranor 120 mg resolved NASH in larger proportions of patients than placebo based on the protocol definition (20% vs 11%; odds ratio = 3.16; 95% confidence interval: 1.22-8.13; P = .018) and the modified definitions (19% vs 9%; odds ratio = 3.52; 95% confidence interval: 1.32-9.40; P = .013). Patients with NASH resolution after receiving elafibranor 120 mg had reduced liver fibrosis stages compared with those without NASH resolution (mean reduction of 0.65 ± 0.61 in responders for the primary outcome vs an increase of 0.10 ± 0.98 in nonresponders; P < .001). Liver enzymes, lipids, glucose profiles, and markers of systemic inflammation were significantly reduced in the elafibranor 120-mg group vs the placebo group. Elafibranor was well tolerated and did not cause weight gain or cardiac events, but did produce a mild, reversible increase in serum creatinine (effect size vs placebo: increase of 4.31 ± 1.19 μmol/L; P < .001).</AbstractText><AbstractText Label="CONCLUSIONS">A post-hoc analysis of data from trial of patients with NASH showed that elafibranor (120 mg/d for 1 year) resolved NASH without fibrosis worsening, based on a modified definition, in the intention-to-treat analysis and in patients with moderate or severe NASH. However, the predefined end point was not met in the intention to treat population. Elafibranor was well tolerated and improved patients' cardiometabolic risk profile. ClinicalTrials.gov number: NCT01694849.</AbstractText><CopyrightInformation>Copyright © 2016 AGA Institute. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ratziu</LastName><ForeName>Vlad</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière, Paris, France; Institute of Cardiometabolism and Nutrition, INSERM, UMRS 938, Paris, France. Electronic address: vlad.ratziu@upmc.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrison</LastName><ForeName>Stephen A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Medicine, Gastroenterology and Hepatology Service, Brooke Army Medical Center, Fort Sam Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Francque</LastName><ForeName>Sven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bedossa</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Pathology, Hôpital Beaujon, University Paris-Denis Diderot, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehert</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, the University of Melbourne, Melbourne, Australia; Faculty of Economics, University of Louvain UCL, Belgique, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serfaty</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Université Pierre et Marie Curie, Hôpital Saint-Antoine, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romero-Gomez</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unit for the Clinical Management of Digestive Diseases and CIBERehd, Hospital Universitario de Valme, Sevilla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boursier</LastName><ForeName>Jérôme</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hepatology Department, University Hospital and LUNAM University, Angers, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdelmalek</LastName><ForeName>Manal</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Duke University, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caldwell</LastName><ForeName>Steve</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Gastroenterology and Hepatology Division, University of Virginia, Charlottesville, Virginia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drenth</LastName><ForeName>Joost</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anstee</LastName><ForeName>Quentin M</ForeName><Initials>QM</Initials><AffiliationInfo><Affiliation>Institute of Cellular Medicine, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hum</LastName><ForeName>Dean</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Genfit SA, Loos, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanf</LastName><ForeName>Remy</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Genfit SA, Loos, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roudot</LastName><ForeName>Alice</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Genfit SA, Loos, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Megnien</LastName><ForeName>Sophie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Genfit SA, Loos, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staels</LastName><ForeName>Bart</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>University of Lille, INSERM UMR1011, Institut Pasteur de Lille, European Genomic Institute for Diabetes, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanyal</LastName><ForeName>Arun</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Virginia Commonwealth University, Richmond, Virginia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>GOLDEN-505 Investigator Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01694849</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>02</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Gastroenterology</MedlineTA><NlmUniqueID>0374630</NlmUniqueID><ISSNLinking>0016-5085</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C585906">2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047188">Chalcones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005765">Gastrointestinal Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047493">PPAR alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047495">PPAR gamma</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011422">Propionates</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Gastroenterology. 2016 May;150(5):1073-6</RefSource><PMID Version="1">27018488</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Ann Hepatol. 2016 Jul-Aug;15(4):604-9</RefSource><PMID Version="1">27236162</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001706" MajorTopicYN="N">Biopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047188" MajorTopicYN="N">Chalcones</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N">Europe</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005765" MajorTopicYN="N">Gastrointestinal Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057194" MajorTopicYN="N">Intention to Treat Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008103" MajorTopicYN="N">Liver Cirrhosis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065626" MajorTopicYN="N">Non-alcoholic Fatty Liver Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047493" MajorTopicYN="N">PPAR alpha</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="Y">agonists</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047495" MajorTopicYN="N">PPAR gamma</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="Y">agonists</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011422" MajorTopicYN="N">Propionates</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012074" MajorTopicYN="N">Remission Induction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">NAFLD</Keyword><Keyword MajorTopicYN="Y">PPARA</Keyword><Keyword MajorTopicYN="Y">PPARD</Keyword><Keyword MajorTopicYN="Y">fatty liver</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Mathurin</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gournay</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nguyen-Khac</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Ledinghen</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Larrey</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tran</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bourliere</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maynard-Muet</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Asselah</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Henrion</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nevens</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cassiman</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Geerts</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moreno</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beuers</LastName><ForeName>U H</ForeName><Initials>UH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galle</LastName><ForeName>P R</ForeName><Initials>PR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spengler</LastName><ForeName>U</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bugianesi</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Craxi</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Angelico</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fargion</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Voiculescu</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gheorghe</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Preotescu</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caballeria</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andrade</LastName><ForeName>R J</ForeName><Initials>RJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crespo</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Callera</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ala</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aithal</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abouda</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Luketic</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huang</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gordon</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pockros</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poordad</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shores</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moehlen</LastName><ForeName>M W</ForeName><Initials>MW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bambha</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clark</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Satapathy</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parekh</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reddy</LastName><ForeName>R K</ForeName><Initials>RK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sheikh</LastName><ForeName>M Y</ForeName><Initials>MY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Szabo</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vierling</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foster</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Umpierrez</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chang</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Box</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gallegos-Orozco</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>01</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>01</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26874076</ArticleId><ArticleId IdType="pii">S0016-5085(16)00140-2</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2016.01.038</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Belgique</li><li>France</li><li>Pays-Bas</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Caroline du Nord</li><li>Gueldre</li><li>Hauts-de-France</li><li>Nord-Pas-de-Calais</li><li>Pays de la Loire</li><li>Texas</li><li>Victoria (État)</li><li>Virginie</li><li>Île-de-France</li></region><settlement><li>Angers</li><li>Lille</li><li>Melbourne</li><li>Nimègue</li><li>Paris</li></settlement><orgName><li>Université Pierre-et-Marie-Curie</li><li>Université de Melbourne</li></orgName></list><tree><noCountry><name sortKey="Romero Gomez, Manuel" sort="Romero Gomez, Manuel" uniqKey="Romero Gomez M" first="Manuel" last="Romero-Gomez">Manuel Romero-Gomez</name></noCountry><country name="France"><region name="Île-de-France"><name sortKey="Ratziu, Vlad" sort="Ratziu, Vlad" uniqKey="Ratziu V" first="Vlad" last="Ratziu">Vlad Ratziu</name></region><name sortKey="Bedossa, Pierre" sort="Bedossa, Pierre" uniqKey="Bedossa P" first="Pierre" last="Bedossa">Pierre Bedossa</name><name sortKey="Boursier, Jerome" sort="Boursier, Jerome" uniqKey="Boursier J" first="Jérôme" last="Boursier">Jérôme Boursier</name><name sortKey="Hanf, Remy" sort="Hanf, Remy" uniqKey="Hanf R" first="Remy" last="Hanf">Remy Hanf</name><name sortKey="Hum, Dean" sort="Hum, Dean" uniqKey="Hum D" first="Dean" last="Hum">Dean Hum</name><name sortKey="Megnien, Sophie" sort="Megnien, Sophie" uniqKey="Megnien S" first="Sophie" last="Megnien">Sophie Megnien</name><name sortKey="Roudot, Alice" sort="Roudot, Alice" uniqKey="Roudot A" first="Alice" last="Roudot">Alice Roudot</name><name sortKey="Serfaty, Lawrence" sort="Serfaty, Lawrence" uniqKey="Serfaty L" first="Lawrence" last="Serfaty">Lawrence Serfaty</name><name sortKey="Staels, Bart" sort="Staels, Bart" uniqKey="Staels B" first="Bart" last="Staels">Bart Staels</name></country><country name="États-Unis"><region name="Texas"><name sortKey="Harrison, Stephen A" sort="Harrison, Stephen A" uniqKey="Harrison S" first="Stephen A" last="Harrison">Stephen A. Harrison</name></region><name sortKey="Abdelmalek, Manal" sort="Abdelmalek, Manal" uniqKey="Abdelmalek M" first="Manal" last="Abdelmalek">Manal Abdelmalek</name><name sortKey="Caldwell, Steve" sort="Caldwell, Steve" uniqKey="Caldwell S" first="Steve" last="Caldwell">Steve Caldwell</name><name sortKey="Sanyal, Arun" sort="Sanyal, Arun" uniqKey="Sanyal A" first="Arun" last="Sanyal">Arun Sanyal</name></country><country name="Belgique"><noRegion><name sortKey="Francque, Sven" sort="Francque, Sven" uniqKey="Francque S" first="Sven" last="Francque">Sven Francque</name></noRegion><name sortKey="Lehert, Philippe" sort="Lehert, Philippe" uniqKey="Lehert P" first="Philippe" last="Lehert">Philippe Lehert</name></country><country name="Pays-Bas"><region name="Gueldre"><name sortKey="Drenth, Joost" sort="Drenth, Joost" uniqKey="Drenth J" first="Joost" last="Drenth">Joost Drenth</name></region></country><country name="Royaume-Uni"><noRegion><name sortKey="Anstee, Quentin M" sort="Anstee, Quentin M" uniqKey="Anstee Q" first="Quentin M" last="Anstee">Quentin M. Anstee</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F60 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001F60 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:26874076
|texte= Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:26874076" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |